Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2023-10-26 Governance Information
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
董事会提名委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Work Rules of the Board Nomination Committee' of Inner Mongolia Datang Pharmaceutical Co., Ltd. It details the composition, responsibilities, procedures, and rules of the board nomination committee. It includes information about the nomination and selection process of directors and senior management, meeting procedures, and confidentiality obligations. There is no financial data, no mention of financial results, no voting results, no legal proceedings, no capital changes, and no report publication announcements. The content is focused on governance structure and internal board committee rules. Therefore, this document fits best under Governance Information (CGR). The document length is 2432 characters, which is relatively short but contains substantive governance content, not just an announcement or notice.
2023-10-26 Chinese
募集资金管理办法
Governance Information Classification · 95% confidence The document is a detailed announcement of the company's internal rules and procedures regarding the management and use of raised funds (募集资金管理办法). It includes sections on the approval process, storage, usage, changes, and supervision of raised funds. The document references board meetings and shareholder approvals but does not contain financial statements or performance data. It is a governance-related policy document rather than a financial report or announcement of voting results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2023-10-26 Chinese
关于召开2023年第二次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2023 second extraordinary general meeting of shareholders for Inner Mongolia Datang Pharmaceutical Co., Ltd. It includes details about the meeting date, voting methods, attendees, agenda items, and registration procedures. It does not contain any financial statements, audit results, or detailed financial analysis. The document is relatively short (2310 characters) and serves as an announcement for a shareholder meeting rather than the meeting materials or results themselves. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-10-26 Chinese
回购股份注销完成暨股份变动公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share repurchase and cancellation, including details on the number of shares repurchased, the change in share capital, and subsequent corporate actions such as registration changes. It includes specific data on shares before and after cancellation and mentions the issuance of a confirmation certificate by the securities registration company. This fits the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback and cancellation of its own shares. The document is short (983 characters) and contains substantive details about the share repurchase and cancellation, not merely an announcement of a report or a certification. Therefore, the correct classification is POS.
2023-10-24 Chinese
关于减少注册资本通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Inner Mongolia Datang Pharmaceutical Co., Ltd. regarding the reduction of registered capital due to the repurchase and cancellation of restricted shares from a 2020 equity incentive plan. It notifies creditors about the capital reduction and provides instructions for debt claims within a specified period. The document is a formal notice to creditors about a corporate capital change, not a financial report or detailed analysis. It does not contain financial statements or management discussion but serves as a regulatory announcement related to capital changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2023-09-05 Chinese
内蒙古上都律师事务所关于内蒙古大唐药业股份有限公司2023年第一次临时股东大会法律意见书
Regulatory Filings
2023-09-03 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.